KPV

As research shows

KPV (Lysine–Proline–Valine) is a C‑terminal tripeptide fragment of α‑melanocyte‑stimulating hormone (α‑MSH) studied for its potent anti‑inflammatory properties without melanotropic side effects. Research demonstrates KPV reduces pro‑inflammatory cytokines in models of inflammatory bowel disease and systemic inflammation. This educational protocol presents a once‑daily subcutaneous approach using a practical dilution for precise insulin‑syringe measurements.

Key benefits

• Anti‑inflammatory activity: Reduces pro‑inflammatory cytokines and modulates immune responses in models of inflammatory bowel disease and systemic inflammation.
• Oral and subcutaneous efficacy: Multiple routes of administration show activity, with subcutaneous injection favored for systemic delivery and consistent bioavailability.
• Wound healing support: Preclinical data suggest KPV may support tissue repair and wound healing processes through inflammatory modulation.
• Generally well tolerated: Occasional mild injection‑site reactions (redness, slight swelling) may occur; systemic side effects are rarely reported in research protocols.